Sugi Predict

Sugi Predict / Targets / SOAT1

SOAT1

Sterol O-acyltransferase 1 · P35610 · SOAT1 on Sugi Atlas →

78,163 patent compounds predicted against SOAT1, 50,929 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Menadione Menadione (SCHEMBL25970) 0.55 4/20
SCHEMBL49598 SCHEMBL49598 0.48 4/20
SCHEMBL14711 SCHEMBL14711 0.50 3/20
SCHEMBL15126 SCHEMBL15126 1.00 2/20
SCHEMBL15127 SCHEMBL15127 1.00 2/20
Oleamide Oleamide (SCHEMBL19788) 1.00 2/20
Oleamide Oleamide (SCHEMBL36321) 1.00 2/20
Oleamide Oleamide (SCHEMBL29585) 0.96 2/20
SCHEMBL43417 SCHEMBL43417 0.78 2/20
Octadecanoic Acid Amide Octadecanoic Acid Amide (SCHEMBL27869) 0.74 2/20
Nonanoamide Nonanoamide (SCHEMBL38252) 0.74 2/20
SCHEMBL42016 SCHEMBL42016 0.74 2/20
SCHEMBL42192 SCHEMBL42192 0.74 2/20
Palmitamide Palmitamide (SCHEMBL43384) 0.74 2/20
SCHEMBL43639 SCHEMBL43639 0.74 2/20
SCHEMBL49285 SCHEMBL49285 0.74 2/20
Difenamizole Difenamizole (SCHEMBL25873) 0.56 2/20
SCHEMBL41307 SCHEMBL41307 0.53 2/20
SCHEMBL42775 SCHEMBL42775 0.53 2/20
SCHEMBL43415 SCHEMBL43415 0.53 2/20

Clinical trials — most relevant to SOAT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Low HDL On Six Weeks Statin Therapy (LOW) Study PHASE4UNKNOWN
Mechanisms Underlying Metabolic Syndrome in Obesity PHASE4COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis PHASE2ACTIVE_NOT_RECRUITING
Hereditary Sensory Neuropathy Serine Trial PHASE2UNKNOWN
Smith-Lemli-Opitz Syndrome and Cholic Acid PHASE1/PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease EARLY_PHASE1COMPLETED
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism nanCOMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism nanCOMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
De Novo Lipogenesis in Severity of NAFLD nanCOMPLETED
Genes Involved in Lipid Disorders nanCOMPLETED
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes nanCOMPLETED
HIV Reverse Cholesterol Transport Study nanUNKNOWN
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
Improving Metabolism With HDL Cholesterol nanCOMPLETED
Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors nanCOMPLETED
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health nanUNKNOWN
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study nanCOMPLETED
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED
A Registration Study for Familial Hypercholesterolemia in Taiwan nanUNKNOWN
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SOAT1 binder may also engage these)

ProteinNameSimilarity
O77761 — 1.000 O77761 →
O77760 — 1.000 O77760 →
Q60457 — 1.000 Q60457 →
Q61263 — 1.000 Q61263 →
O70536 — 0.997 O70536 →
Q5R7H4 — 0.981 Q5R7H4 →
O88908 — 0.980 O88908 →
Q9VRR2 — 0.979 Q9VRR2 →
Q7TQM4 — 0.979 Q7TQM4 →
Q8N609 — 0.977 Q8N609 →
Q6R8G6 — 0.977 Q6R8G6 →
B3H6K1 — 0.977 B3H6K1 →
A0AAS4 — 0.976 A0AAS4 →
SOAT2 Sterol O-acyltransferase 2 0.976 landscape →
Q6R8G5 — 0.976 Q6R8G5 →
LBR Delta(14)-sterol reductase LBR 0.975 landscape →
Q7Z3F1 — 0.975 Q7Z3F1 →
Q93ZF5 — 0.975 Q93ZF5 →
Q9LJK3 — 0.975 Q9LJK3 →
P23913 — 0.975 P23913 →
O08984 — 0.975 O08984 →
F4I8Q7 — 0.975 F4I8Q7 →
Q96PB1 — 0.974 Q96PB1 →
Q5R9A7 — 0.974 Q5R9A7 →
Q8C428 — 0.974 Q8C428 →
Q8QZR0 — 0.974 Q8QZR0 →
A0A161IUT7 — 0.974 A0A161IUT7 →
Q94CA0 — 0.974 Q94CA0 →
Q5BPZ5 — 0.974 Q5BPZ5 →
O82244 — 0.974 O82244 →